Compare UNP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNP | NVO |
|---|---|---|
| Founded | 1862 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1B | 197.4B |
| IPO Year | 2005 | N/A |
| Metric | UNP | NVO |
|---|---|---|
| Price | $258.74 | $47.41 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 11 |
| Target Price | ★ $275.55 | $51.00 |
| AVG Volume (30 Days) | 2.9M | ★ 11.4M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | 2.08% | ★ 3.19% |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $19,533,000,000.00 | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $4.29 | $3.70 |
| P/E Ratio | $90.56 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $214.32 | $35.12 |
| 52 Week High | $279.70 | $71.80 |
| Indicator | UNP | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 64.78 |
| Support Level | $217.43 | $45.62 |
| Resistance Level | $272.75 | $47.79 |
| Average True Range (ATR) | 6.45 | 1.41 |
| MACD | -1.47 | 0.28 |
| Stochastic Oscillator | 18.88 | 99.14 |
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24.5 billion of revenue in 2025 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.